India, Feb. 12 -- Larimar Therapeutics Inc. (LRMR) announced Monday positive top-line data from phase 2 dose exploration study from 25 mg and 50 mg cohorts of Nomlabofusp in patients with Friedreich's Ataxia or FA.
In pre-market activity on Nasdaq, Larimar shares were losing more than 37 percent to trade at $4.87.
The shares had gained around 24 percent on last Friday to close at $7.76.
The clinical-stage biotechnology company focused on complex rare diseases said it has successfully completed its four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp (CTI-1601) in participants with FA.
In the trial, Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in frataxin levels in all evaluate...